ABSTRACT
INTRODUCTION
Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality 1 . Prediction of PTB and resultant intervention are the bases for its effective prevention. Measurement of cervical length (CL) on transvaginal sonography (TVS) performed in the second trimester is currently one of the best predictive tests for spontaneous PTB (sPTB) 2, 3 . In singleton pregnancies with short CL and mostly without prior sPTB, vaginal progesterone has been shown to prevent sPTB [4] [5] [6] . In singleton pregnancies with prior sPTB and TVS-CL < 25 mm, cerclage is associated with significant prevention of recurrent PTB and of neonatal morbidity and mortality 7 . Additional interventions to prevent PTB are still needed, as a significant proportion of women with a short CL deliver preterm despite treatment with vaginal progesterone and/or cerclage. Furthermore, the option of a cerclage may not be feasible in resource-poor settings.
Use of a cervical pessary has been studied for possible prevention of PTB in singleton pregnancies with short TVS-CL, but results from randomized controlled trials (RCTs) are so far contradictory. One RCT showed pessary use to be associated with prevention of PTB 8 , whereas two more recent studies did not 9, 10 .
The objective of this study was to determine if pessary use can prevent PTB in women with singleton pregnancy, with short TVS-CL and without prior sPTB.
METHODS

Study design and participants
This was an open-label randomized clinical trial conducted at the Hospital of the University of Pennsylvania, Pennsylvania Hospital, Thomas Jefferson University Hospital, Geisinger Health System and Temple University. Approval was obtained from the institutional review boards of the participating sites. Federal Drug Administration Investigational Device Exemption was obtained and the study was registered with ClinicalTrials .gov (NCT02056652).
Women presenting at the five sites at 18 + 0 to 23 + 6 weeks' gestation for fetal anatomy ultrasound scan between 17 March 2014 and 29 July 2016 underwent CL measurement on TVS. CL was measured by sonographers using the CLEAR criteria of the Perinatal Quality Foundation 11 . Exclusion criteria were CL > 25 mm, multiple pregnancy, prior sPTB between 16 and 36 + 6 weeks, age < 18 or > 50 years, inability to understand the English language, ruptured membranes, abnormal Pap test, lethal fetal structural anomaly, fetal chromosomal abnormality, present or planned cerclage, vaginal bleeding, suspicion of chorioamnionitis, ballooning of membranes outside the cervix into the vagina, CL = 0 mm, painful regular uterine contractions or placenta previa. Treatment with vaginal progesterone was recommended to all women with CL ≤ 20 mm prior to enrollment.
Written consent was obtained from eligible women by trained study personnel. Consenting subjects were randomized centrally by a web-based system (REDCap™) using random blocks of two, four and six to either receive a pessary or no pessary. Randomization was stratified by study site and CL (CL ≤ 20 mm and CL > 20-25 mm). The pessary was not available at sites outside of the trial.
Pessaries were inserted by maternal-fetal medicine staff trained centrally in proper placement. Pessary insertion training consisted of a didactic session and a hands-on session. All staff were required to demonstrate competence in pessary placement on a live model. Bioteque cup pessaries, designed for the treatment of mild uterine prolapse, were used. This pessary is very similar to the Arabin pessary (Figure 1) , as is the approach to its insertion. The smaller diameter of the pessary should encompass the cervix, and the side of the pessary with the larger diameter should face the introitus 12 . Pessary sizing was determined based on gravidity, body mass index and vaginal laxity, thus a pelvic examination was performed prior to pessary placement.
Subjects were contacted monthly to ascertain information, including on hospital and office visits other than routine prenatal care appointments, and on potential complications and symptoms related to the cervical pessary. Although there was no specific screening at randomization or follow-up, any genitourinary infections diagnosed during the current pregnancy were recorded. These included urinary tract infection, bacterial vaginosis, chlamydia, gonorrhea, genital herpes simplex virus outbreak (primary or recurrence), trichomonas and syphilis.
Pessary removal was scheduled for 37 weeks' gestation. Indications for pessary removal prior to 37 weeks included patient request, preterm prelabor rupture of membranes (PPROM), labor and vaginal bleeding. Pessaries were also removed if necessary to evaluate subjects with preterm contractions or other conditions. Pessaries were reinserted by a trained provider if the symptoms resolved and the cervix was dilated less than 3 cm.
Outcome measures
The primary outcome was PTB < 37 weeks. Planned secondary maternal outcomes included: PTB < 34, < 28 and < 24 weeks; sPTB < 37, < 34, < 28 and < 24 weeks; gestational age at delivery; birth weight; chorioamnionitis; genitourinary infection; intrauterine fetal demise; and Cesarean delivery. sPTB included those with spontaneous onset of labor and those with rupture of membranes prior to labor. Neonatal outcome included neonatal death (death between birth and 28 days of age) and composite adverse neonatal outcome, which consisted of necrotizing enterocolitis, intraventricular hemorrhage (Grade 3 or 4), respiratory distress syndrome, bronchopulmonary dysplasia, retinopathy, blood culture-proven sepsis and neonatal death. Data were collected regarding potential significant adverse maternal effects including heavy vaginal bleeding, injury to vagina, cervix or bladder (e.g. erosion or fistula), uterine rupture and maternal intolerance to pessary (request for removal secondary to discomfort and/or discharge).
Sample-size calculation
Calculation of sample size was based on a reduction in the incidence of PTB before 37 weeks from 30% 5, 6 in the no-pessary group to 15% in the pessary group 8 , with a power of 80%. To detect this difference at a significance level of 5%, a total of 242 subjects, with 121 subjects in each arm, was required. The Data Safety and Monitoring Committee recommended that subject recruitment be stopped on 30 June 2016, due to the fact that the two primary recruiting sites would be unable to continue to enroll subjects in this trial, given precedence of a competing National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Unit Network (MFMU) pessary trial after their entrance into the NICHD MFMU Network. No interim analysis was performed.
Statistical analysis
Statistical analysis was based on the intention-to-treat principle. Comparisons between the two groups were made using the Mann-Whitney U-test and Fisher's exact test. P-values for all hypotheses were two sided and P-values less than 0.05 were considered to be significant. The risk of PTB before 37 weeks was quantified using relative risk and 95% CIs using logistic regression (generalized linear modeling using Stata 14; Statacorp LP, College Station, TX, USA). The interval from randomization until delivery was compared for the two groups using Kaplan-Meier analysis. Statistical analysis (excluding the general linear modeling) was performed using Statistical Package for Social Sciences (SPSS) v.23.0 (IBM Inc., Armonk, NY, USA). This study was reported following the CONSORT guidelines. This trial was registered on ClinicalTrials.gov (NCT 02056652).
RESULTS
In total, 17 383 women underwent CL screening on TVS. Included in intention-to-treat analysis (n = 58)
Figure 2
Flowchart of recruitment and study of women presenting at 18 + 0 to 23 + 6 weeks' gestation with singleton pregnancy and cervical length (CL) ≤ 25 mm on transvaginal sonography (TVS), randomized to treatment with or without pessary. *No study coordinator available to discuss study with patient. sPTB, spontaneous preterm birth. Data presented as median (interquartile range) or n (%). *Education not known for one case in pessary group. BMI, body mass index. Data are given as n (%) or median (interquartile range). *Includes urinary tract infection, bacterial vaginosis, chlamydia, gonorrhea, herpes simplex virus and trichomonas. PPROM, preterm prelabor rupture of membranes; PTB, preterm birth. 122 (31.2%) agreed to randomization. Sixty-one (50%) women were randomized to the pessary group and 61 (50%) to the no-pessary group. One subject in the pessary group was found to be ineligible due to prior sPTB, which was discovered 6 days after enrollment in the trial. Her pessary was removed and she was withdrawn from the trial. Three subjects in the no-pessary group were lost to follow-up. In total, 60 subjects assigned to the pessary group and 58 assigned to the no-pessary group were included in the intention-to-treat analysis. Baseline characteristics of the study population, including median gestational age (20.9 vs 20.7 weeks; P = 0.86) and CL (17.6 vs 19.0 mm; P = 0.54) at randomization, were similar between the groups (Table 1) . Of the 60 women without prior sPTB who were randomized to the pessary group, 42 received a size 3 Bioteque and 18 a size 4 Bioteque pessary. There were no significant differences between the pessary and no-pessary groups in the number of subjects who received treatment with vaginal progesterone (84% vs 91%, P = 0.485), rate of PTB < 37 weeks (43% vs 40%; relative risk 1.09; 95% CI, 0.71-1.68), nor any other obstetric (Table 2) or neonatal ( outcome. A Kaplan-Meier survival curve failed to show a significant difference in time to delivery between the pessary and no-pessary groups ( Figure 3 ). The mean time to delivery was 15.7 (95% CI, 14.0-17.5) weeks in the pessary group and 15.9 (95% CI, 13.8-17.7) weeks in the no-pessary group (logrank test P = 0.48). Forty-four (73.3%) subjects in the pessary group and 28 (48.3%) in the no-pessary group reported vaginal discharge at at least one of the monthly telephone calls after enrollment (P = 0.002). Gestational age at pessary removal and delivery according to indication for pessary removal is presented in Table 4 . Twenty-three (38.3%) subjects had their pessary removed due to preterm labor or PPROM, including two subjects who had pessary removals at 22 + 5 and 22 + 6 weeks' gestation due to presentation with bulging membranes. These two subjects had cerclages placed after pessary removal and delivered at 35 + 6 and 22 + 6 weeks, respectively. Two subjects had pessaries removed and then replaced after evaluation in order to rule out preterm labor. One subject had her pessary repositioned due to discomfort during sexual intercourse and two additional subjects who reported discomfort had their pessaries exchanged for a different size (one larger and one smaller).
DISCUSSION
The Bioteque pessary was found to have no effect on the incidence of PTB in singleton pregnancies with TVS-CL ≤ 25 mm before 24 weeks and without prior sPTB. Pessary use had no effect on composite adverse neonatal outcome.
Three other RCTs have been published that reported on pessary use for short mid-trimester TVS-CL in singleton pregnancies [8] [9] [10] . These trials used the Arabin pessary and included women with a history of sPTB. Characteristics of these three trials and of the current trial are summarized in Table 5 . Two trials enrolled women with CL ≤ 25 mm 8, 10 and the third enrolled women with CL < 25 mm 9 . In the study of Nicolaides et al. 10 , subjects with TVS-CL ≤ 15 mm were treated with vaginal progesterone. Data on the use of progesterone were not reported in Goya Table 4 Gestational age (GA) at pessary removal and at delivery, according to indication for removal in women presenting at 18 + 0 to 23 + 6 weeks' gestation with singleton pregnancy, cervical length ≤ 25 mm and no prior spontaneous preterm birth Data are given as median (range) or as individual values when n ≤ 3. *Two subjects requested pessary removal after initial insertion at time of study enrollment (one expressed concern regarding interference with sexual intercourse and one did not provide reason); third subject requested pessary removal at 36.3 weeks due to discomfort during sexual intercourse. †Pessary fell out during sexual intercourse. IUFD, intrauterine fetal death; IUGR, intrauterine growth restriction; PE, pre-eclampsia; PPROM, preterm prelabor rupture of membranes. Only first author of each study is given. GA, gestational age; NA, information not available; PPROM, preterm prelabor rupture of membranes; PTB, preterm birth; sPTB, spontaneous preterm birth.
et al. 8 or Hui et al. 9 . In these three trials, similar to as in our trial, pessaries were removed at 37 weeks' gestation unless an earlier indication for removal was present. In the first of these RCTs, Goya et al. 8 (n = 380) reported significant decreases in sPTB < 28, 34 and 37 weeks and PTB < 34 weeks with pessary use and better composite neonatal outcome in the pessary compared with the no-pessary group 8 . The pessary was not removed in the case of PPROM. However, only three of 190 (1.6%) subjects in the pessary group had PPROM. Hui et al. 9 (n = 108) and Nicolaides et al. 10 (n = 924) reported no significant differences in PTB or neonatal outcome 9, 10 . A meta-analysis of these three RCTs showed no significant effect on sPTB or neonatal outcome of pessary use in singleton pregnancies with short mid-trimester TVS-CL compared with no pessary 13 . The results of the current RCT are consistent with those of Hui et al. 9 , Nicolaides et al. 10 and the meta-analysis of all three RCTs 13 .
A potential reason for the lack of demonstrable effect of treatment with a pessary in our trial is that any reduction in PTB may have been due to treatment with progesterone and that there is no added benefit of pessary.
There are a number of differences between the current trial and the three prior ones. First, the Bioteque pessary was used in this study and women with a history of sPTB were not eligible. Despite this, the study population may have been at increased risk for PTB compared with the other three RCTs. Mean gestational age and CL at the time of enrollment were lower in our trial and the majority of subjects were from a predominantly African-American inner-city population. The rates of sPTB and PTB in the no-pessary group in our trial were comparable with the rates observed in Goya et al. 8 and substantially increased compared with Nicolaides et al. 10 and Hui et al. 9 ( Table 5 ). The rate of PPROM was substantially higher in our trial.
In prior studies of women similar to the ones in this study (singleton pregnancies without prior sPTB), the incidence of CL ≤ 25 mm before 24 weeks on a single TVS-CL screen varied from approximately 1% to 3% [14] [15] [16] . This is consistent with the incidence of 2.4% in our study.
Use of a pessary appeared to be safe and was well tolerated by the majority of women despite the high rate of reported vaginal discharge. Of note is that, although the rate of vaginal discharge was significantly higher in the pessary group, rate of genitourinary infection did not differ between the groups. Treatment with a pessary may be associated with discomfort as well as dislodgement and/or expulsion during sexual intercourse. One subject requested pessary removal secondary to discomfort during sexual intercourse, one had the pessary expelled during sexual intercourse and declined replacement and a third subject required repositioning of the pessary due to dislodgement during sexual intercourse with resultant discomfort. A fourth subject requested pessary removal immediately after pessary insertion due to apprehension regarding potential discomfort with sexual intercourse. Thus, in addition to counseling patients about increased vaginal discharge associated with pessary use, patients should be counseled on potential dislodgment and/or expulsion of the pessary during sexual intercourse.
A strength of our study was the rigor of the training required for pessary insertion. In addition to didactic and hands-on training, all staff were required to demonstrate competence in pessary placement on a live model. Additional strengths include the randomized design, adherence to CLEAR guidelines for TVS-CL screening and compliance with CONSORT guidelines.
The main limitation was the small sample size due to the fact that the study was stopped before planned enrollment was completed. In order to reach significance using our predetermined sample size, we would need for the next 60 subjects randomized to the pessary group to have a 10% rate of PTB, assuming that the rate in the no-pessary group remained at 40%.
Although the Bioteque and Arabin pessaries are similar in shape and the diameters of the outer and inner rings are similar, the height of the Bioteque pessary is less than that of the Arabin pessary. The size 3 Bioteque pessary measurements (outer ring diameter × inner ring diameter × height) are 65 mm × 33 mm × 17 mm and the Arabin pessary measurements are 65 mm × 32 mm × 25 mm ( Figure 1) ; we do not know if this difference in pessary height is of clinical significance. Of note is that all the RCTs to date have used the Arabin pessary with varying success. We chose to use the Bioteque pessary as the shape and width of the inner and outer rings were similar to those of the Arabin pessary, and because it is available clinically in the USA.
There are several ongoing RCTs evaluating the use of the pessary in the prevention of PTB in women with short TVS-CL. In addition, there are plans for a prospective independent patient data meta-analysis, for which our data will be an important component. The goals of this meta-analysis are to provide the power to perform a number of clinically relevant subgroup analyses, including stratification by CL and progesterone use, and possibly to identify specific characteristics/subgroups that may be associated with pessary effectiveness in preventing PTB.
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